Literature DB >> 1440489

A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants.

A K Banerjee1, J Pearson, E L Gilliland, D Goss, J D Lewis, Y Stirling, T W Meade.   

Abstract

A total of 333 patients with stable intermittent claudication at recruitment were followed up for 6 years to determine risk factors associated with subsequent mortality. Cardiovascular diseases were the underlying cause of death in 78% of the 114 patients who died. The strongest independent predictor of death during the follow-up period was the plasma fibrinogen level, an increase of 1 milligram being associated with a nearly two-fold increase in the probability of death within the next 6 years. Age, low ankle/brachial pressure index and a past history of myocardial infarction also increased the probability of death during the study period. The plasma fibrinogen level is a valuable index of those patients with stable intermittent claudication at high risk of early mortality. The results also provide further evidence for the involvement of fibrinogen in the pathogenesis of arterial disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1440489

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  Peripheral Arterial Disease.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

2.  Fibrinogen and cardiovascular disease.

Authors:  T W Meade
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

3.  Sedentary behavior is associated with impaired biomarkers in claudicants.

Authors:  Breno Q Farah; Raphael M Ritti-Dias; Polly S Montgomery; Ana I Casanegra; Federico Silva-Palacios; Andrew W Gardner
Journal:  J Vasc Surg       Date:  2015-10-27       Impact factor: 4.268

4.  Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.

Authors:  G Ken-Dror; F Drenos; S E Humphries; P J Talmud; A D Hingorani; M Kivimäki; M Kumari; K A Bauer; J H Morrissey; H A Ireland
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

5.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.

Authors:  Tom Meade; Riaz Zuhrie; Claire Cook; Jackie Cooper
Journal:  BMJ       Date:  2002-11-16

6.  Late thromboembolic complication from a Palmaz stent in the common iliac artery.

Authors:  B M Stoeckelhuber; U Szeimies; F A Spengel; G Kueffer
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

7.  Association Between Daily Steps at Moderate Cadence and Vascular Outcomes in Patients With Claudication.

Authors:  Andrew W Gardner; Polly S Montgomery; Ming Wang; Biyi Shen
Journal:  J Cardiopulm Rehabil Prev       Date:  2022-01-01       Impact factor: 2.081

Review 8.  Influence of fibrinogen on cardiovascular disease.

Authors:  W B Kannel
Journal:  Drugs       Date:  1997       Impact factor: 9.546

9.  Prothrombin time derived fibrinogen determination on Sysmex CA-6000.

Authors:  A S Lawrie; S J McDonald; G Purdy; I J Mackie; S J Machin
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

10.  Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.

Authors:  G Y Lip; G D Lowe; A Rumley; F G Dunn
Journal:  Br Heart J       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.